ViiV Healthcare announces a favorable opinion from the CHMP for Rukobia (fostemsavir), the first binding inhibitor in the treatment of adults with multidrug-resistant HIV
Saturday, December 12, 2020
ViiV Healthcare, the international HIV company majority-owned by GlaxoSmithKline plc (“GSK”), and of which Pfizer Inc. and Shionogi Limited are shareholders, today announces that the Common Medicines Committee Human (CHMP) from the European Medicines Agency (EMA) has issued a favorable opinion recommending the approval of the prolonged-release tablets of Rukobia (fostemsavir) 600 mg, a new binding inhibitor for the treatment of HIV infection -1. In combination with other antiretrovirals, fostemsavir is indicated for the treatment of adults with multidrug-resistant HIV-1 infection for whom it is not otherwise possible to initiate a suppressive antiviral protocol. 1
Deborah Waterhouse, CEO of ViiV Healthcare, said: “While considerable advances have been made in the treatment of HIV in recent decades, a specific population of adults with multidrug-resistant HIV-1 infection fails to maintain viral suppression with currently available drugs. Without effective new options, this group of people are at risk for the progression of AIDS. It is for this reason that the favorable opinion of the CHMP for fostemsavir was eagerly awaited and represents a major step forward in ensuring that no one is left behind, regardless of the stage of the disease. We are committed to conducting innovative research to meet the diverse needs of the HIV community, and the CHMP's favorable opinion is the result of a thorough research process, development and development. We won't stop until we find new ways to treat HIV, and hopefully somehow cure it. "
The marketing authorization (MA) for fostemsavir is supported by data from the pivotal Phase III BRIGHTE study, which evaluated the safety and efficacy of fostemsavir in combination with optimized DMARD in patients. heavily pretreated adults with multidrug-resistant HIV, many of whom had advanced HIV when they entered the study. In the randomized group, 60% (n = 163/272) of people who received fostemsavir in addition to an optimized DMARD chosen by the researchers achieved an undetectable HIV viral load and clinically relevant improvements in blood counts. CD4 + T cells at week 96. 2,3
The most common adverse reactions occurring during treatment were diarrhea (24%), headache (17%), nausea (15%), rash (12%), abdominal pain (12%), and vomiting (11%). The most common adverse events leading to treatment discontinuation were infections (3%). The most serious adverse reaction was immune reconstitution inflammatory syndrome. 1
The European Commission's marketing authorization is expected in the coming months. Under the designation Rukobia, fostemsavir was recently approved by the United States Food and Drug Administration (FDA) on July 2, 2020, and further regulatory submissions have been made globally.
ViiV Healthcare's mission is to ensure that no one living with HIV is left behind. As the only pharmaceutical company fully focused on HIV and AIDS, ViiV Healthcare is dedicated to providing a wide range of treatments to meet the needs of diverse people living with HIV. The company continues to invest in groundbreaking research and development programs to provide a portfolio of innovative treatment options that will help be a game-changer for people with HIV.
About Rukobia (fostemsavir)
Fostemsavir is an HIV-1 binding inhibitor. After oral administration, fostemsavir is converted to temsavir, which is then absorbed and exerts antiviral activity by attaching directly to the glycoprotein 120 (gp120) subunit on the surface of the virus, thus preventing HIV from seeding. attach to the CD4 + T cells of the host's immune system and the virus to infect these cells and multiply. Since Rukobia is the first antiretroviral therapy to target this stage of the viral cycle, there is no demonstrated resistance to other classes of antiretroviral drugs, which could help patients who have become resistant to most other drugs. .
About BRIGHTE
The BRIGHTE trial is an international Phase III, partially randomized, double-blind, placebo-controlled study in 371 heavily pretreated adults with HIV-1 who are resistant to various drugs. All trial participants were required to have a viral load of ≥400 copies / mL and to be pre-treated with ≤2 classes of antiretroviral drugs at baseline doses due to resistance, intolerability, contraindication. indication, or other safety concern. The trial participants were enrolled in a randomized or non-randomized cohort, and defined as follows:
- In the randomized group (n = 272), participants were taking 1, or at most 2, antiretroviral agents that were fully active and available at the time of selection and that could be combined as part of effective maintenance therapy. Randomized participants received, blinded, either fostemsavir 600 mg twice daily (n = 203) or placebo (n = 69), in addition to their current failing treatment, for 8 days of functional monotherapy. After day 8, randomized patients received open label fostemsavir 600 mg twice daily plus investigator-selected optimized background therapy (OBT).
- In the non-randomized group (n = 99), participants were not taking a fully active and approved antiretroviral agent at the time of screening. Non-randomized participants received open label fostemsavir 600 mg twice daily plus optimized DMARD from day 1. Use of one or more investigational drugs as a component of optimized DMARD was permitted in the non-randomized group.
Primary endpoint analysis, based on the adjusted mean drop in HIV-1 RNA from day 1 to day 8 in the randomized group, demonstrated the superiority of fostemsavir over placebo (decline of 0.79 versus 0.17 log10 copies / mL, respectively; P <0.0001, population exposed according to the intention to treat principle (ITT)).
In the randomized group, HIV-1 RNA <40 copies / mL was achieved in 53% and 60% of subjects at weeks 24 and 96, respectively (ITT, Snapshot algorithm). The mean changes in CD4 + cell count from baseline continued to increase over time (90 cells / mm3 at week 24 and 205 cells / mm3 at week 96). The most common side effect (incidence ≥5%, all grades) was nausea. The proportion of participants who discontinued fostemsavir treatment due to an adverse event was 7% at week 96 (randomized: 5% and non-randomized: 12%). In the non-randomized group, HIV-1 RNA <40 copies / mL was achieved in 37% of subjects at weeks 24 and 96. At these stages of the trial, the proportion of subjects with HIV-1 RNA <200 copies / mL was 42% and 39%, respectively (ITT, Snapshot algorithm). The mean changes in CD4 + cell count from baseline increased over time: 41 cells / mm3 at week 24 and 119 cells / mm3 at week 96. Most common adverse reactions reported in the non-randomized group were fatigue (7%), nausea (6%) and diarrhea (6%).
Important safety information in the EU
THERAPEUTIC INDICATIONS
In combination with other antiretrovirals, Rukobia is indicated for the treatment of adults with multidrug-resistant HIV-1 for whom it is not otherwise possible to initiate a suppressive antiviral protocol.
DOSAGE AND METHOD OF ADMINISTRATION
The recommended dose is 600 mg of fostemsavir, twice a day.
CONTRAINDICATIONS
Hypersensitivity to fostemsavir or to any component of the formulation.
Co-administration with potent inducers of cytochrome P450 (CYP) 3A, since large decreases in plasma concentrations of temsavir may occur, and therefore lead to loss of virological response.
WARNINGS AND PRECAUTIONS
Cases of immune reconstitution syndrome have been reported in patients treated with combination ARV therapy.
Prolongation of the QTc interval:
Use RUKOBIA with caution in patients with a history of QT interval prolongation, when co-administered with a drug with known risk of torsade de pointes, or pre-existing heart disease. Elderly patients may be more susceptible to drug-induced QT prolongation.
Patients with hepatitis B or C virus co-infection:
Elevations of hepatic transaminases may occur in patients with hepatitis B or C virus coinfection: elevations of hepatic transaminases have been observed in a greater proportion of subjects with hepatitis B virus coinfection. HBV and / or HCV, compared to those with mono-infection with HIV.
Recorded range of antiviral activity:
It is recommended that Rukobia not be used to treat infections caused by AE subtype M strains of HIV-1.
Risk of adverse reactions and loss of virological response due to drug interactions:
ADVERSE REACTIONS
The most commonly observed adverse reactions during treatment were diarrhea, headache, and nausea.
INTERACTIONS WITH OTHER MEDICINAL PRODUCTS.
Concomitant use of RUKOBIA and certain other medicines may cause known or potentially significant drug interactions, some of which may lead to 1) loss of therapeutic effect of RUKOBIA and possible development of resistance due to reduced exposure to temsavir; 2) possible prolongation of the QTc interval caused by increased exposure to temsavir.
Doses of oral contraceptives should not contain more than 30 µg of ethinyl estradiol per day.
USE IN SPECIFIC POPULATIONS:
The safety and efficacy profile of Rukobia has not been established in children and adolescents below 18 years of age. There are only limited data from the use of Rukobia during pregnancy. As a precaution, the use of Rukobia should be avoided during pregnancy.
About ViiV Healthcare
ViiV Healthcare is an international pharmaceutical company specializing in HIV, founded in November 2009 by GlaxoSmithKline (London Stock Exchange: GSK) and Pfizer (New York Stock Exchange: PFE) with the aim of advancing the delivery of treatment and healthcare. '' improve care for people living with HIV or at risk of HIV infection. Shionogi joined the entity in October 2012. The company's aim is to take a deeper and broader interest in HIV / AIDS than any other company has done so far, to use a new approach to make available innovative and effective drugs in the treatment and prevention of HIV and to support communities affected by HIV. For more information on the company, its management, its product portfolio,www.viivhealthcare.com .
About GSK
GSK, a global healthcare and pharmaceutical research company, is committed to improving quality of life by helping men and women do more, feel better, and live longer. For more information, please visit www.gsk.com/about-us .
Caution regarding forward-looking statements
GSK cautions investors that all forward-looking statements or projections made by GSK, including those contained in this press release, are subject to risks and uncertainties that could cause actual results to differ materially from expectations. These factors include, but are not limited to, those described in Section 3.D “Risk Factors and Uncertainties” in the Company's Annual Report on Form 20-F for 2019 and any impact of the COVID-19 pandemic.
Registered in England and Wales:
No. 3888792
The head office :
980 Great West Road
Brentford, Middlesex
TW8 9GS
References
1 Summary of Product Characteristics - European Medicines Agency. Summary of advice for Rukobia. Available at https://www.ema.europa.eu/en/medicines/human/summaries-opinion/rukobia . Last consulted in December 2020.
2 Kozal, M., et al. 2020. Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection. New England Journal of Medicine, 382 (13), pp. 1232-1243.
3 Lataillade, M., et al. 2020. Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study. The Lancet, Vol 7 Nov 2020 pp. 740-751.
The text of the press release resulting from a translation should in no way be considered official. The only authentic version of the press release is that of the press release in its original language. The translation will always have to be compared to the source text, which will set a precedent.
Contacts
ViiV Healthcare, Media Relations:
Patricia O'Connor (Global): +44 (0) 7469 375019 (London)
Audrey Abernathy: +1 916 054 521 (US)
GSK, Inquiry
: Media Relations:
Simon Steel: +44 (0) 20 8047 5502 (London)
Tim Foley: +44 (0) 20 8047 5502 (London)
Kristen Neese: +1 804 217 8147 (Philadelphia)
Kathleen Quinn: +1 202 603 5003 (Washington)
Analyst / Investor Relations:
Sarah Elton-Farr: +44 (0) 20 8047 5194 (London)
Sonya Ghobrial: +44 (0) 7392 784784 (consumers)
James Dodwell: +44 (0) 20 8047 2406 (London)
Jeff McLaughlin: +1 215 751-7002 (Philadelphia)
Frannie DeFranco: +1 215 751-4855 (Philadelphia)